Patents by Inventor Motoki Kuhara
Motoki Kuhara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9540447Abstract: Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homolog 10 (FZD10) in a subject is provided.Type: GrantFiled: July 30, 2014Date of Patent: January 10, 2017Assignee: ONCOTHERAPY SCIENCE, INC.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Chikako Fukukawa, Motoki Kuhara
-
Patent number: 9493550Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.Type: GrantFiled: October 3, 2014Date of Patent: November 15, 2016Assignees: Osaka University, The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Yoshinobu Okuno, Mikihiro Yunoki, Shoji Ideno, Masatoshi Oshita, Motoki Kuhara, Masatoshi Momota
-
Patent number: 9181328Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.Type: GrantFiled: January 31, 2013Date of Patent: November 10, 2015Assignees: OSAKA UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD., DEPARTMENT OF MEDICAL SCIENCES MINISTRY OF PUBLIC HEALTHInventors: Mayo Yasugi, Motoki Kuhara, Jotika Boon-Long, Kazuhito Fujiyama, Ritsuko Koketsu, Kazuyoshi Ikuta
-
Patent number: 8975378Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.Type: GrantFiled: December 24, 2009Date of Patent: March 10, 2015Assignees: Osaka University, The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Yoshinobu Okuno, Mikihiro Yunoki, Shoji Ideno, Masatoshi Oshita, Motoki Kuhara, Masatoshi Momota
-
Publication number: 20150051379Abstract: Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.Type: ApplicationFiled: July 30, 2014Publication date: February 19, 2015Inventors: Yusuke NAKAMURA, Toyomasa KATAGIRI, Chikako FUKUKAWA, Motoki KUHARA
-
Publication number: 20150044225Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.Type: ApplicationFiled: October 3, 2014Publication date: February 12, 2015Inventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Yoshinobu Okuno, Mikihiro Yunoki, Shoji Ideno, Masatoshi Oshita, Motoki Kuhara, Masatoshi Momota
-
Publication number: 20140377262Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.Type: ApplicationFiled: January 31, 2013Publication date: December 25, 2014Applicants: OSAKA UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD., DEPARTMENT OF MEDICAL SCIENCESInventors: Mayo Yasugi, Motoki Kuhara, Jotika Boon-Long, Kazuhito Fujiyama, Ritsuko Koketsu, Kazuyoshi Ikuta
-
Patent number: 8846038Abstract: Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.Type: GrantFiled: June 14, 2013Date of Patent: September 30, 2014Assignee: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Chikako Fukukawa, Motoki Kuhara
-
Patent number: 8697068Abstract: Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.Type: GrantFiled: April 28, 2010Date of Patent: April 15, 2014Assignee: Oncotherapy Science, IncInventors: Yusuke Nakamura, Toyomasa Katagiri, Chikako Fukukawa, Motoki Kuhara
-
Publication number: 20130295108Abstract: Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.Type: ApplicationFiled: June 14, 2013Publication date: November 7, 2013Inventors: Yusuke NAKAMURA, Toyomasa KATAGIRI, Chikako FUKUKAWA, Motoki KUHARA
-
Patent number: 8221751Abstract: The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Also, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-associated disease; and a method for in vivo imaging of FZD10 in a subject.Type: GrantFiled: August 24, 2006Date of Patent: July 17, 2012Assignee: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsuru, Keigo Endo, Motoki Kuhara, Kasumi Yagi
-
Publication number: 20120156242Abstract: Antigenic peptides are provided that can be used to induce global neutralizing antibodies, or antibodies reactive against a wide range of influenza A virus strains. The antigenic peptide can correspond to SEQ ID NO: 34 (EKEVLVLWG), SEQ ID NO: 2 (KFDKLYIWG), SEQ ID NO: 71(QEDLLVLWG), SEQ ID NO: 51 (EGRINYYWTLLEP), SEQ ID NO: 3 (PSRISIYWTIVKP), and/or SEQ ID NO: 82 (SGRMEFFWTILKP).Type: ApplicationFiled: June 16, 2010Publication date: June 21, 2012Inventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Akifumi Yamashita, Norihito Kawashita, Mikihiro Yunoki, Yoshinobu Okuno, Shoji Ideno, Motoki Kuhara
-
Publication number: 20110319600Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.Type: ApplicationFiled: December 24, 2009Publication date: December 29, 2011Inventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Yoshinobu Okuno, Mikihiro Yunoki, Shoji Ideno, Masatoshi Oshita, Motoki Kuhara, Masatoshi Momota
-
Patent number: 8003098Abstract: The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.Type: GrantFiled: February 22, 2007Date of Patent: August 23, 2011Assignee: Oncotherapy Science, Inc.Inventors: Shuichi Nakatsuru, Megumi Yoshikawa, Shinichi Hiroshima, Yoshiro Kishi, Motoki Kuhara, Shiyo Nishida, Midori Shinohara
-
Publication number: 20080248011Abstract: The present invention provides HIDE1 as novel monocyte markers. Since HIDE1 are membrane proteins, monocytes can be specifically detected by using antibodies that bind to HIDE1. Further, HIDE1-positive monocytes can also be collected from peripheral blood or the like using a cell sorter, magnet, or such. Monocytes that can be prepared based on the present invention are useful in cell immunotherapy.Type: ApplicationFiled: January 25, 2005Publication date: October 9, 2008Applicant: MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD.Inventors: Tomoko Nakagawa, Shunsuke Kurei, Shingo Toji, Ayako Okabe, Motoki Kuhara, Yoshiro Kishi, Ichiro Yahara
-
Publication number: 20060276631Abstract: A mast cell surface antigen, DNA thereof and an antibody against the antigen are provided. The amino acid sequence of this mast cell surface antigen is the translation of the coding region of its DNA. The base sequence of this DNA has been clarified in the following manner. Namely, mast cells obtained by incubating cord blood monocular cells are co-incubated with primary culture of fibroblasts to give connective tissue type mast cells (MC-TC). Then mRNA is extracted from this MC-TC cell extraction and a cDNA library is constructed therefrom. Immunological screening is carried out with the use of anti-MC-TC antiserum and the base sequence of the positive clone thus obtained is identified. Owing to the clarification of the amino acid sequence of this mast cell antigen, it becomes possible to reveal the role of mast cells in the pathology of allergic diseases and thus an antibody against mast cells can be easily obtained.Type: ApplicationFiled: May 2, 2006Publication date: December 7, 2006Inventors: Makoto Kawai, Tadashi Okada, Fukiko Atsumi, Masao Shibata, Motoki Kuhara
-
Patent number: 7045597Abstract: A mast cell surface antigen, DNA thereof and an antibody against the antigen are provided. The amino acid sequence of this mast cell surface antigen is the translation of the coding region of its DNA. The base sequence of this DNA has been clarified in the following manner. Namely, mast cells obtained by incubating cord blood monocular cells are co-incubated with primary culture of fibroblasts to give connective tissue type mast cells (MC-TC). Then mRNA is extracted from this MC-TC cell extraction and a cDNA library is constructed therefrom. Immunological screening is carried out with the use of anti-MC-TC antiserum and the base sequence of the positive clone thus obtained is identified. Owing to the clarification of the amino acid sequence of this mast cell antigen, it becomes possible to reveal the role of mast cells in the pathology of allergic diseases and thus an antibody against mast cells can be easily obtained.Type: GrantFiled: January 4, 2001Date of Patent: May 16, 2006Assignee: Medical & Biological Laboratories Co., Ltd.Inventors: Makoto Kawai, Tadashi Okada, Fukiko Atsumi, Masao Shibata, Motoki Kuhara
-
Publication number: 20040152870Abstract: A mast cell surface antigen, DNA thereof and an antibody against the antigen are provided. The amino acid sequence of this mast cell surface antigen is the translation of the coding region of its DNA. The base sequence of this DNA has been clarified in the following manner. Namely, mast cells obtained by incubating cord blood monocular cells are co-incubated with primary culture of fibroblasts to give connective tissue type mast cells (MC-TC). Then mRNA is extracted from this MC-TC cell extraction and a cDNA library is constructed therefrom. Immunological screening is carried out with the use of anti-MC-TC antiserum and the base sequence of the positive clone thus obtained is identified. Owing to the clarification of the amino acid sequence of this mast cell antigen, it becomes possible to reveal the role of mast cells in the pathology of allergic diseases and thus an antibody against mast cells can be easily obtained.Type: ApplicationFiled: November 4, 2003Publication date: August 5, 2004Inventors: Makoto Kawai, Tadashi Okada, Fukiko Atsumi, Masao Shibata, Motoki Kuhara